PMID- 31721319
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1468-3083 (Electronic)
IS  - 0926-9959 (Linking)
VI  - 34
IP  - 5
DP  - 2020 May
TI  - Adjuvant therapy for cutaneous melanoma: a systematic review and network 
      meta-analysis of new therapies.
PG  - 956-966
LID - 10.1111/jdv.16074 [doi]
AB  - New drugs have been recently approved as adjuvant therapies for melanoma. In this 
      Bayesian network meta-analysis, we aimed to assess the best therapeutic option in 
      terms of recurrence-free survival (RFS), overall survival (OS) and adverse events 
      (AEs). PubMed, Embase, Cochrane library and the American Society of Clinical 
      Oncology databases were searched from inception until 20 August 2018. We 
      estimated adjusted hazard ratios (HRs) for RFS and OS and relative odds ratios 
      (ORs) for AEs and surface under the cumulative ranking (SUCRA) probabilities were 
      calculated. A number of 872 records were identified, and six were finally 
      included in the meta-analysis. A total of 4244 patients in six studies were 
      randomized. The following therapies were considered in the selected studies: 
      combined dabrafenib and trametinib, vemurafenib, nivolumab, ipilimumab and 
      pembrolizumab. Nivolumab demonstrated the highest probability (75.1%) of being 
      the best in term of RFS, followed by dabrafenib+trametinib, pembrolizumab, 
      ipilimumab and vemurafenib; however, OS was not estimable. Concerning AEs, 
      pembrolizumab and nivolumab showed the highest probability to be less associated 
      with any and 3-4 grade AEs (83.1% and 64.4%, respectively). In conclusion, all 
      new drugs are highly effective in adjuvant setting, and the best choice is 
      dependent of patient's context.
CI  - (c) 2019 European Academy of Dermatology and Venereology.
FAU - Longo, C
AU  - Longo C
AD  - Department of Dermatology, University of Modena and Reggio Emilia, Modena, Italy.
AD  - Centro Oncologico ad Alta Tecnologia Diagnostica, Azienda Unita Sanitaria Locale 
      - IRCCS di Reggio Emilia, Reggio Emilia, Italy.
FAU - Pampena, R
AU  - Pampena R
AD  - Centro Oncologico ad Alta Tecnologia Diagnostica, Azienda Unita Sanitaria Locale 
      - IRCCS di Reggio Emilia, Reggio Emilia, Italy.
FAU - Lallas, A
AU  - Lallas A
AD  - First Department of Dermatology, Aristotle University, Thessaloniki, Greece.
FAU - Kyrgidis, A
AU  - Kyrgidis A
AD  - First Department of Dermatology, Aristotle University, Thessaloniki, Greece.
FAU - Stratigos, A
AU  - Stratigos A
AD  - First Department of Dermatology and Venereology, National and Kapodistrian 
      University of Athens, A. Sygros Hospital, Athens, Greece.
FAU - Peris, K
AU  - Peris K
AD  - Institute of Dermatology, Catholic University, Rome, Italy.
AD  - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
FAU - Garbe, C
AU  - Garbe C
AD  - Center of Dermato-oncology, University Department of Dermatology, Eberhard Karls 
      University, Tuebingen, Germany.
FAU - Pellacani, G
AU  - Pellacani G
AD  - Department of Dermatology, University of Modena and Reggio Emilia, Modena, Italy.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20200106
PL  - England
TA  - J Eur Acad Dermatol Venereol
JT  - Journal of the European Academy of Dermatology and Venereology : JEADV
JID - 9216037
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols
MH  - Bayes Theorem
MH  - Humans
MH  - *Melanoma/drug therapy
MH  - Network Meta-Analysis
MH  - Randomized Controlled Trials as Topic
MH  - *Skin Neoplasms/drug therapy
EDAT- 2019/11/14 06:00
MHDA- 2021/05/15 06:00
CRDT- 2019/11/14 06:00
PHST- 2019/07/02 00:00 [received]
PHST- 2019/10/30 00:00 [accepted]
PHST- 2019/11/14 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2019/11/14 06:00 [entrez]
AID - 10.1111/jdv.16074 [doi]
PST - ppublish
SO  - J Eur Acad Dermatol Venereol. 2020 May;34(5):956-966. doi: 10.1111/jdv.16074. 
      Epub 2020 Jan 6.